BRPI0810733A2 - Uso do modulador do receptor s1p - Google Patents

Uso do modulador do receptor s1p

Info

Publication number: BRPI0810733A2
Authority: BR; Brazil
Prior art keywords: receiver modulator; modulator; receiver
Prior art date: 2007-05-04

Application number

BRPI0810733-5A2A

Other languages

English (en)

Inventor

Yves-Alain Barde

Graeme Bilbe

Ruben Deogracias

Rainer R Kuhn

Tomoya Matsumoto

Anis Khusro Mir

Anna Svenja Schubart

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-04

Filing date

2008-05-01

Publication date

2014-10-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39588961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0810733(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-05-01 Application filed by Novartis Ag filed Critical Novartis Ag

2014-10-21 Publication of BRPI0810733A2 publication Critical patent/BRPI0810733A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0810733-5A2A 2007-05-04 2008-05-01 Uso do modulador do receptor s1p BRPI0810733A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US91598507P	2007-05-04	2007-05-04
PCT/EP2008/055405 WO2008135522A1 (en)	2007-05-04	2008-05-01	Use of s1p receptor modulator

Publications (1)

Publication Number	Publication Date
BRPI0810733A2 true BRPI0810733A2 (pt)	2014-10-21

Family

ID=39588961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0810733-5A2A BRPI0810733A2 (pt)	2007-05-04	2008-05-01	Uso do modulador do receptor s1p

Country Status (12)

Country	Link
US (4)	US20100093672A1 (pt)
EP (1)	EP2142184B1 (pt)
JP (5)	JP2010526116A (pt)
KR (3)	KR20100021430A (pt)
CN (2)	CN101674819A (pt)
AU (1)	AU2008248648B2 (pt)
BR (1)	BRPI0810733A2 (pt)
CA (1)	CA2684953C (pt)
ES (1)	ES2707576T3 (pt)
MX (1)	MX2009011943A (pt)
RU (1)	RU2498796C2 (pt)
WO (1)	WO2008135522A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2142184B1 (en) *	2007-05-04	2018-10-24	Novartis AG	Use of s1p receptor modulator
CN101973898B (zh) *	2010-09-09	2013-06-19	南京明生医药技术有限公司	2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
SG191286A1 (en)	2011-01-07	2013-07-31	Novartis Ag	Immunosuppressant formulations
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2012307535A1 (en) *	2011-09-13	2014-04-03	Novartis Ag	Combinations comprising a S1P receptor modulator
US8946301B2 (en) *	2011-11-29	2015-02-03	Als Therapy Development Institute	Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis
WO2016135644A1 (en)	2015-02-26	2016-09-01	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
CN106466479A (zh) *	2015-08-18	2017-03-01	周意	脑源性神经营养因子前体蛋白用作治疗情感障碍的靶点
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en)	2017-03-09	2023-04-18	Novartis Ag	Solid forms comprising an oxime ether compound, compositions and methods of use thereof
CN118662488A (zh)	2020-02-06	2024-09-20	田边三菱制药株式会社	肌痛性脑脊髓炎/慢性疲劳症候群治疗剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004529100A (ja) *	2001-01-30	2004-09-24	ユニバーシティオブバージニアパテントファウンデーション	スフィンゴシン−１−ホスフェートレセプターのアゴニストおよびアンタゴニスト
AU2002320470A1 (en) *	2001-07-11	2003-01-29	Musc Foundation For Research Development	Modulators of ceramidase and methods of use based thereon
KR100913269B1 (ko)	2001-09-27	2009-08-21	교린 세이야꾸 가부시키 가이샤	디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제
DE60329073D1 (de)	2002-01-18	2009-10-15	Merck & Co Inc	Edg-rezeptoragonisten
MY150088A (en) *	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
WO2005025553A2 (en) *	2003-09-12	2005-03-24	Neuronova Ab	Treatment of disorders of nervous systemsystem with fty720
WO2005041899A2 (en)	2003-11-03	2005-05-12	University Of Virginia Patent Foundation	Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2005105146A1 (en)	2004-05-03	2005-11-10	Novartis Ag	Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
EP2384749A1 (en) *	2004-11-29	2011-11-09	Novartis AG	Dosage regimen of an S1P receptor agonist
WO2006064616A1 (ja)	2004-12-16	2006-06-22	Matsushita Electric Industrial Co., Ltd.	生ごみ処理装置
GB0504544D0 (en)	2005-03-04	2005-04-13	Novartis Ag	Organic compounds
GB0612721D0 (en) *	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
AU2007338771A1 (en) *	2006-12-19	2008-07-03	Merrimack Pharmaceuticals, Inc.	Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
EP2142184B1 (en) *	2007-05-04	2018-10-24	Novartis AG	Use of s1p receptor modulator

2008
- 2008-05-01 EP EP08749978.6A patent/EP2142184B1/en active Active
- 2008-05-01 KR KR1020097025249A patent/KR20100021430A/ko not_active Ceased
- 2008-05-01 AU AU2008248648A patent/AU2008248648B2/en not_active Ceased
- 2008-05-01 JP JP2010506902A patent/JP2010526116A/ja active Pending
- 2008-05-01 CN CN200880014840A patent/CN101674819A/zh active Pending
- 2008-05-01 CN CN201410584780.9A patent/CN104337808A/zh active Pending
- 2008-05-01 BR BRPI0810733-5A2A patent/BRPI0810733A2/pt not_active IP Right Cessation
- 2008-05-01 CA CA2684953A patent/CA2684953C/en not_active Expired - Fee Related
- 2008-05-01 US US12/598,771 patent/US20100093672A1/en not_active Abandoned
- 2008-05-01 KR KR1020157002829A patent/KR101528125B1/ko not_active Expired - Fee Related
- 2008-05-01 MX MX2009011943A patent/MX2009011943A/es not_active Application Discontinuation
- 2008-05-01 ES ES08749978T patent/ES2707576T3/es active Active
- 2008-05-01 KR KR1020147031025A patent/KR101526835B1/ko not_active Expired - Fee Related
- 2008-05-01 WO PCT/EP2008/055405 patent/WO2008135522A1/en not_active Ceased
- 2008-05-01 RU RU2009144846/15A patent/RU2498796C2/ru not_active IP Right Cessation
2011
- 2011-12-05 US US13/310,941 patent/US20120245129A1/en not_active Abandoned
2013
- 2013-05-13 US US13/893,295 patent/US20140011884A1/en not_active Abandoned
- 2013-12-05 US US14/097,623 patent/US9265754B2/en active Active
- 2013-12-09 JP JP2013254024A patent/JP5764643B2/ja active Active
2015
- 2015-06-15 JP JP2015119902A patent/JP2015199756A/ja not_active Withdrawn
2017
- 2017-02-09 JP JP2017022557A patent/JP2017105823A/ja not_active Withdrawn
2019
- 2019-11-06 JP JP2019201411A patent/JP2020037567A/ja active Pending

Also Published As

Publication number	Publication date
KR20140141716A (ko)	2014-12-10
JP2020037567A (ja)	2020-03-12
JP2014088395A (ja)	2014-05-15
JP2017105823A (ja)	2017-06-15
WO2008135522A1 (en)	2008-11-13
US20120245129A1 (en)	2012-09-27
AU2008248648B2 (en)	2012-02-23
KR20100021430A (ko)	2010-02-24
RU2498796C2 (ru)	2013-11-20
US20100093672A1 (en)	2010-04-15
MX2009011943A (es)	2009-11-13
EP2142184B1 (en)	2018-10-24
CN104337808A (zh)	2015-02-11
CN101674819A (zh)	2010-03-17
KR20150017391A (ko)	2015-02-16
US20140011884A1 (en)	2014-01-09
ES2707576T3 (es)	2019-04-04
RU2009144846A (ru)	2012-08-10
US20140235610A1 (en)	2014-08-21
AU2008248648A1 (en)	2008-11-13
KR101528125B1 (ko)	2015-06-11
JP5764643B2 (ja)	2015-08-19
CA2684953C (en)	2016-08-09
KR101526835B1 (ko)	2015-06-05
CA2684953A1 (en)	2008-11-13
US9265754B2 (en)	2016-02-23
EP2142184A1 (en)	2010-01-13
JP2015199756A (ja)	2015-11-12
JP2010526116A (ja)	2010-07-29

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-02-26	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2019-06-25	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2512 DE 26-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2022-07-12	B350	Update of information on the portal [chapter 15.35 patent gazette]

Publication	Publication Date	Title
BRPI0821668A2 (pt)	2015-06-16	Uso
IS8842A (is)	2009-08-11	Kjarnviðtaka bindimiðlar.
BRPI0813653A2 (pt)	2014-12-30	Compostos de imidazotiazol moduladores de sirtuína
BRPI0813651A2 (pt)	2014-12-30	Compostos de tiazolopiridina moduladores de sirtuína
EP2179061A4 (en)	2010-09-08	GREAT LIKE RECEPTOR MODULATORS
BRPI0820407A2 (pt)	2015-05-26	Uso de anticorpos anti-cd40
BRPI0815661A2 (pt)	2015-02-18	Dispositivo de distribuição com travamento
DK2952177T3 (da)	2021-04-26	Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
BRPI0818189A2 (pt)	2015-04-14	Uso de um monoterpeno
BRPI0821784A2 (pt)	2015-09-29	receptor de navegação
BRPI0807453A2 (pt)	2014-05-20	Preparação sólida
ATE509022T1 (de)	2011-05-15	Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
DK2262808T3 (da)	2013-11-04	Chemokinreceptormodulatorer
EP2213436A4 (en)	2011-09-28	CLAMPING DEVICE
DK2193504T3 (da)	2013-02-04	Vejafgiftssystem
DK2297100T3 (da)	2012-12-17	Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
DE502007006120D1 (de)	2011-02-10	Hochverfügbares Kommunikationssystem
PL2203089T3 (pl)	2016-07-29	Udoskonalone urządzenie poziomujące
DK2125048T3 (da)	2014-10-13	Præparat
GB0701992D0 (en)	2007-03-14	Grehlin Receptor Modulators
BRPI0812525A2 (pt)	2015-09-22	dispositivo de travamento
BRPI0822061A2 (pt)	2015-06-23	Moduladores do receptor canabinoide
FR2921207B1 (fr)	2014-12-19	Adaptateur de raccordement
EP2227553A4 (en)	2011-01-19	Lac expression system
DK2193283T3 (da)	2013-06-10	Låseanordning